Molecular signaling of G‐protein‐coupled receptor in chronic heart failure and associated complications.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 23, doi. 10.1002/ddr.21627
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2020 AND VI 81 AND IP 1
Results: 15
1
2
Cover Image, Volume 81, Issue 1.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. i, doi. 10.1002/ddr.21644
- Publication type:
- Article
3
Emerging role of primary heterogeneous nucleation in pharmaceutical crystallization.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 3, doi. 10.1002/ddr.21622
- By:
- Publication type:
- Article
4
Discovery of novel halogenated 8‐hydroxyquinoline‐based anti‐MRSA agents: In vitro and QSAR studies.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 127, doi. 10.1002/ddr.21611
- By:
- Publication type:
- Article
5
Erratum.
- Published in:
- 2020
- Publication type:
- Correction Notice
6
The use of aliskiren as an antifibrotic drug in experimental models: A systematic review.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 114, doi. 10.1002/ddr.21610
- By:
- Publication type:
- Article
7
A new potential anti‐cancer beta‐carboline derivative decreases the expression levels of key proteins involved in glioma aggressiveness: A proteomic investigation.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 32, doi. 10.1002/ddr.21600
- By:
- Publication type:
- Article
8
Issue Information ‐ TOC.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 1, doi. 10.1002/ddr.21548
- Publication type:
- Article
9
A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 102, doi. 10.1002/ddr.21609
- By:
- Publication type:
- Article
10
Chronic administration of Cl‐amidine, a pan‐peptidylarginine deiminase inhibitor, does not reverse bone loss in two different murine models of osteoporosis.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 93, doi. 10.1002/ddr.21608
- By:
- Publication type:
- Article
11
L6H9 attenuates LPS‐induced acute lung injury in rats through targeting MD2.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 85, doi. 10.1002/ddr.21607
- By:
- Publication type:
- Article
12
Novel 5‐(1‐aryl‐1H‐pyrazol‐3‐yl)‐1H‐tetrazoles as glycogen phosphorylase inhibitors: An in vivo antihyperglycemic activity study.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 70, doi. 10.1002/ddr.21606
- By:
- Publication type:
- Article
13
In vitro and in vivo evaluation of radiolabeled methyl N‐[5‐(3′‐halobenzoyl)‐1H‐benzimidazol‐2‐yl]carbamate for cancer radiotherapy.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 62, doi. 10.1002/ddr.21604
- By:
- Publication type:
- Article
14
Novel histone deacetylase inhibitors bearing a 4‐piperidin‐4‐yl‐triazole scaffold as antitumor agents.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 52, doi. 10.1002/ddr.21603
- By:
- Publication type:
- Article
15
Novel antimicrobial peptide discovery using machine learning and biophysical selection of minimal bacteriocin domains.
- Published in:
- Drug Development Research, 2020, v. 81, n. 1, p. 43, doi. 10.1002/ddr.21601
- By:
- Publication type:
- Article